Komori
TAUNS Laboratories (197A) · InitiativeReframed

Development of New Core Technologies and an Inspection Platform

First written in FY2024. 5 of 9 entries say "Advanced", first in 2026-06-30. Latest entry: FY2026.

9entries
3years
6from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2024AdvancedFY2025 – 2026-08-182024: 120242025: 120252026: 72026
Same theme, other companies
Development and improvement of testing technologies and diagnostic products for POCTA theme 7 companies write about · 1 as a headwind · 11 as a tailwind

0 other companies' latest entry also says "Reframed".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
  1. FY2026ReframedAnnual report

    「In addition to our core POCT business, we are introducing new testing platforms, including contract testing and software as a medical device (SaMD), and expanding the scope of our testing and diagnostics business.」

    The focus shifted from listing individual technology development projects to a multi-platform business concept combining POCT, contract testing and SaMD.
  3. FY2025RaisedAnnual report

    「We also aim to provide multi-omics testing services through investment in new diagnostic technologies, including approaches that analyze the condition of immune cells in the body, genomics, epigenomics, and the microbiome.」

    The scope has expanded beyond new antibodies and immune-cell analysis to genomics, epigenomics, and the microbiome, with the company explicitly presenting a concept for multi-omics testing services.
  4. FY2024First statedAnnual report

    「In addition to D-IA, we are developing a compact blood-testing instrument capable of quantitatively measuring biomarkers in blood and a urine-testing system for the simple measurement of urinary biomarkers, creating high-performance antibodies using new antibody-generation technologies, developing diagnostic technologies based on approaches that analyze the condition of immune cells in the body, and pursuing whole-genome testing, among other initiatives.」

    The company is pursuing multiple technology areas in parallel, including compact blood testing, urine testing, new antibodies, immune-cell analysis, and whole-genome testing, rather than focusing solely on D-IA.
Moved together

"IP and Technology Partnership Investments Toward the 10-Year Business Vision" moved the same way as this thread, in the same document, in 5 of its 8 moves.

522222★123456
  1. ★This thread
  2. 1IP and Technology Partnership Investments Toward the 10-Year Business Vision5×
  3. 2High-sensitivity, multi-analyte, quantitative POCT enabled by D-IA2×
  4. 3Expansion into non-infectious disease areas, including chronic diseases, cancer and kidney disease2×
  5. 4Free-Float Ratio and Post-Listing Share Liquidity2×
  6. 5Clinical testing contract services provided by タウンズクリニカルラボ2×
  7. 6Productivity Gains Through a New Core Business System and Medical Data Platform2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for TAUNS Laboratories yet. It last moved in the Business Alliances of 2026-08-20: "Advanced".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Development of New Core Technologies and an Inspection Platform | TAUNS Laboratories,Inc. (197A) | Komori